Black Diamond Therapeutics, Inc. cash flow to debt ratio of 157.68% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Black Diamond Therapeutics, Inc.'s free cash flow has increased -147.53% from $-62.30M last year to $29.61M, signaling increasing performance

Black Diamond Therapeutics, Inc.'s debt to equity ratio is 0.18, which means that the company's assets are healthy financed, signaling financial stability.

Black Diamond Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.27 last year to 0.18 today, signaling strengthened financials

Black Diamond Therapeutics, Inc. has a net cash position, so leverage is healthy.

Black Diamond Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Black Diamond Therapeutics, Inc. has insufficient data to evaluate this check.

Black Diamond Therapeutics, Inc.'s short-term assets of $132.44M exceed its short-term liabilities of $15.73M

Black Diamond Therapeutics, Inc.'s return on assets of -34.04% is lower than the 5.00% threshold, indicating inefficient asset utilization

Black Diamond Therapeutics, Inc.'s return on equity of -38.80%, is lower than 15.00%, indicating bad performance

Black Diamond Therapeutics, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Black Diamond Therapeutics, Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

Black Diamond Therapeutics, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Black Diamond Therapeutics, Inc. has a free cash flow yield of 26.10%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Black Diamond Therapeutics, Inc.'s yearly earnings has increased -132.10% since last year from $-69.68M to $22.37M, signaling increasing performance

Black Diamond Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -45.91% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Black Diamond Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Black Diamond Therapeutics, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Black Diamond Therapeutics, Inc. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

Black Diamond Therapeutics, Inc. has insufficient data to evaluate this check.

Black Diamond Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Black Diamond Therapeutics, Inc. is undervalued relative to its fair value price of 2.58 based on EBITDA multiple model

Black Diamond Therapeutics, Inc. has an EV/EBITDA ratio of 0.16x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Black Diamond Therapeutics, Inc. has insufficient data to evaluate this check.

Black Diamond Therapeutics, Inc. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

Black Diamond Therapeutics, Inc. has a price-to-book ratio of 1.18x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Black Diamond Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue